When the CAR Targets Scar | NEJM
Clinical Implications of Basic Research from The New England Journal of Medicine — When the CAR Targets Scar
Related Articles
Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis | NEJM
Nerandomilast (BI 1015550) is an orally administered preferential inhibitor of phosphodiesterase 4B with antifibrotic and immunomodulatory effects. In a phase 2 trial involving patients with…
Navigational Bronchoscopy or Transthoracic Needle Biopsy for Lung Nodules | NEJM
Each year, millions of pulmonary nodules are identified incidentally or through lung cancer screening, and many involve biopsy to distinguish cancer from benign processes. Both…
Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease | NEJM
Base editors can correct disease-causing genetic variants. After a neonate had received a diagnosis of severe carbamoyl-phosphate synthetase 1 deficiency, a disease with an estimated…
Interview with Alice Chen on responding to the U.S. administration’s threats to health and physicians’ values and maintaining hope in difficult times. | NEJM
Audio Interview from the New England Journal of Medicine — Interview with Alice Chen on responding to the U.S. administration’s threats to health and physicians’…
Personalized Gene Editing to Treat an Inborn Error of Metabolism | NEJM
In this editorial, the authors describe the foundations of an N-of-1 gene-editing study to treat an infant with a urea-cycle disorder.
Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease | NEJM
Base editors can correct disease-causing genetic variants. After a neonate had received a diagnosis of severe carbamoyl-phosphate synthetase 1 deficiency, a disease with an estimated…
Personalized Gene Editing to Treat an Inborn Error of Metabolism | NEJM
In this editorial, the authors describe the foundations of an N-of-1 gene-editing study to treat an infant with a urea-cycle disorder.
Personalized Gene Editing to Treat an Inborn Error of Metabolism | NEJM
In this editorial, the authors describe the foundations of an N-of-1 gene-editing study to treat an infant with a urea-cycle disorder.
Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis | NEJM
Throughout the course of multiple sclerosis, gradually progressive neurologic impairment can occur, which has been called disability accrual. Current disease-modifying therapies for multiple sclero…
Antiretroviral Therapy for Children with HIV in Africa | NEJM
Quick Take Video Summary from The New England Journal of Medicine — Antiretroviral Therapy for Children with HIV in Africa